You are here

HAE

CRISPR on the Cusp: The Promise and the Pain Points

CRISPR on the Cusp: The Promise and the Pain Points

BioSpace

Intellia Therapeutics

Flag link:

Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med

Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med

Fierce Biotech

Intellia Therapeutics

hereditary angiodema

Flag link:

CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

Drugs.com

clinical trials

Flag link:

Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

Yahoo Finance

Ionis Pharmaceuticals

clinical trials

hereditary angiodema

Flag link:

Pharvaris studies of rare disease drug put on hold by FDA

Pharvaris studies of rare disease drug put on hold by FDA

BioPharma Dive

hereditary angiodema

Flag link:

CSL reports Phase III data for garadacimab to treat hereditary angioedema

CSL reports Phase III data for garadacimab to treat hereditary angioedema

Clinical Trials Arena

clinical trials

hereditary angiodema

Flag link:

Intellia doses first patient as hereditary angioedema gene editing therapy lands in clinic

Intellia doses first patient as hereditary angioedema gene editing therapy lands in clinic

Fierce Biotech

Intellia Therapeutics

clinical trials

Flag link:

Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says

Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says

Fierce Pharma

hereditary angiodema

Flag link:

BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo

BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo

Fierce Pharma

Flag link:

Regulatory progress for two biotechs stalls as FDA requests more information

Regulatory progress for two biotechs stalls as FDA requests more information

MedCity News

Y-mAbs Therapeutics

Flag link:

FDA slaps a hold on KalVista's PhII study of an HAE drug, raising a red flag on preclinical results

FDA slaps a hold on KalVista's PhII study of an HAE drug, raising a red flag on preclinical results

Endpoints

clinical trials

Flag link:

Mid-stage angioedema hit sends Kalvista though the roof

Mid-stage angioedema hit sends Kalvista though the roof

EP Vantage

hereditary angiodema

Flag link:

BioCryst takes on Takeda, CSL with FDA approval for Orladeyo, the first pill to prevent HAE attacks

BioCryst takes on Takeda, CSL with FDA approval for Orladeyo, the first pill to prevent HAE attacks

Fierce Pharma

Flag link:

Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE

Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE

Endpoints

Flag link:

BioCryst Plans to Raise $100 Million

BioCryst Plans to Raise $100 Million

Motley Fool

Flag link:

Pharming gets FDA approval for new facility to make HAE drug Ruconest

Pharming gets FDA approval for new facility to make HAE drug Ruconest

Fierce Pharma

drug manufacturing

Flag link:

After BioCryst fizzle, a new oral HAE player emerges

After BioCryst fizzle, a new oral HAE player emerges

Endpoints

clinical trials

Flag link:

Upcoming events – key tests approach for Biogen and Kalvista

Upcoming events – key tests approach for Biogen and Kalvista

EP Vantage

multiple sclerosis

Flag link:

BioCryst shares are blasted as a PhIII HAE 'success' underwhelms analysts

BioCryst shares are blasted as a PhIII HAE 'success' underwhelms analysts

Endpoints

clinical trials

Flag link:

Shire's drug for rare swelling disorder wins European panel green light

Shire's drug for rare swelling disorder wins European panel green light

Reuters

Flag link:

Pages